{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:01:00Z","timestamp":1773820860554,"version":"3.50.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Slow and ultraslow infusions of low-dose thrombolytic therapy (TT) have emerged as promising alternatives for managing mechanical prosthetic valve thrombosis (PVT), potentially enhancing thrombus resolution while reducing bleeding complications. This study presents real-world clinical outcomes using low-dose alteplase regimens administered according to a pharmacist-led institutional protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cross-sectional study was conducted at a multispecialty quaternary care hospital in the United Arab Emirates. Twelve patients presenting with heart failure symptoms and confirmed PVT received low-dose alteplase thrombolytic regimens. The protocol involved either a slow infusion (25 mg over 6 hours) or an ultraslow infusion (25 mg over 25 hours). Clinical characteristics, treatment regimens, and outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most patients presented with New York Heart Association (NYHA) class II and III symptoms, representing 50% and 41.7% of cases, respectively. Mitral valve thrombosis was observed in 58.3% of patients, aortic valve thrombosis in 33.3%, and one patient exhibited thrombi involving both valves. The ultraslow infusion protocol was applied in 91.7% of cases. The median total alteplase dose administered was 47.9 mg (range 25 to 125 mg), delivered over one to five doses. Clinical success, defined as complete or partial resolution of valve thrombosis, was achieved in 50% of patients after the first dose and 83.3% after the second dose. One patient experienced an ischemic stroke. Bleeding complications occurred in one third of patients, with only one major bleeding event. All patients survived at one-month follow-up, and one patient required valve surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low-dose slow and ultraslow alteplase thrombolytic regimens demonstrated favorable clinical outcomes in patients with symptomatic PVT within a real-world clinical setting. Despite limitations inherent to a retrospective observational design and small sample size, these findings support pharmacologic thrombolysis as a potential alternative to surgery in selected patients. Larger prospective studies are required to further define optimal thrombolytic regimens and patient selection criteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1732701","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:00:05Z","timestamp":1773817205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low dose slow and ultraslow thrombolytic therapy for patients with prosthetic valve thrombosis: a pharmacist-led protocol experience from a Middle Eastern quaternary care center"],"prefix":"10.3389","volume":"13","author":[{"given":"Ziad","family":"Sadik","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Cleveland Clinic Abu Dhabi","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Al Zaman","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Sheikh Shakhbout Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emna","family":"Abidi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Cleveland Clinic Abu Dhabi","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Khalil","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine of Case, Western Reserve University","place":["Cleveland, OH, United States"]},{"name":"Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Al Badarin","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine of Case, Western Reserve University","place":["Cleveland, OH, United States"]},{"name":"Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Ghisulal","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Atallah","sequence":"additional","affiliation":[{"name":"Clinical Affairs, College of Pharmacy, Dubai Medical University","place":["Dubai, United Arab Emirates"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","article-title":"Prosthetic heart valve thrombosis","volume":"68","author":"Dangas","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1161\/cir.0000000000000923","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/eurheartj\/ehx141","article-title":"Mechanical versus bioprosthetic aortic valve replacement","volume":"38","author":"Head","year":"2017","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemostasis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jtcvs.2003.12.013","article-title":"Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute","volume":"127","author":"D\u00fcrrleman","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jcmg.2012.10.016","article-title":"Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis","volume":"6","author":"\u00d6zkan","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"B8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ahj.2015.04.025","article-title":"Ultraslow thrombolytic therapy: a novel strategy in the management of prosthetic mechanical valve thrombosis and the predictors of outcome: the ultra-slow PROMETEE trial","volume":"170","author":"\u00d6zkan","year":"2015","journal-title":"Am Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jacc.2021.12.027","article-title":"Thrombolysis or surgery in patients with obstructive mechanical valve thrombosis: the multicenter HATTUSHA study","volume":"79","author":"\u00d6zkan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B10","first-page":"567","article-title":"Recommendations for the management of prosthetic valve thrombosis","volume":"14","author":"Lengyel","year":"2005","journal-title":"J Heart Valve Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11239-006-4969-y","article-title":"Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients","volume":"21","author":"C\u00e1ceres-L\u00f3riga","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jcmg.2012.12.003","article-title":"Prosthetic valve thrombosis","volume":"6","author":"Vemulapalli","year":"2013","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1732701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:00:06Z","timestamp":1773817206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1732701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":12,"alternative-id":["10.3389\/fcvm.2026.1732701"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1732701","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1732701"}}